Know Cancer

forgot password

A Phase I Trial of STA-4783 in Patients Receiving Paclitaxel for Treatment of Solid Tumors

Phase 2
18 Years
Not Enrolling

Thank you

Trial Information

A Phase I Trial of STA-4783 in Patients Receiving Paclitaxel for Treatment of Solid Tumors

Inclusion Criteria:

- Male and female patients greater than or equal to 18 years of age with histologically
confirmed malignancy that is metastatic or unresectable and for which no standard
therapy exists.

- Patients must not have received prior chemotherapy or radiation for greater than or
equal to 4 weeks before study enrollment.

- Patients may be entered if they have received prior radiation therapy involving less
than or equal to 30% of the bone marrow. Any prior radiation therapy must have been
administered greater than or equal to 4 weeks before study enrollment and the patient
must be recovered from the acute toxic effects of the treatment prior to study entry.

- Patients may be enrolled with a history of treated brain metastases that are
clinically stable for greater than or equal to 4 weeks prior to enrollment.

- ECOG Performance Status of less than or equal to 2.

- Life expectancy of greater than 12 weeks.

- No peripheral neuropathy > grade 1 on NCI CTC version 2 scale, no history of stroke
or other significant neurological limitations as determined by the investigator.

- Patients must have acceptable organ and marrow function at screening and pre-dose
visits as defined below.

- Absolute neutrophil count greater than or equal to 1,500/ul

- Platelets greater than or equal to 100,000 cells/ul

- Total bilirubin must be within normal limits

- AST(SGOT) less than or equal to 2.5 times the upper limit of normal

- Serum creatinine < 1.5 mg/dl or a measured creatine clearance greater than or equal
to 50 mL/min

- Electrocardiogram without evidence of clinically significant conduction abnormalities
or active ischemia as determined by investigator.

- The effects of STA-4783 on the developing human fetus are unknown, however taxanes
are known to be teratogenic. Therefore, women of childbearing potential (defined as
women less than or equal to 50 years of age or history of amenorrhea for < 12 months
prior to study entry) must agree to use adequate contraception (hormonal or barrier
method of birth control; abstinence) prior to study entry and for the duration of
study participation.

- Ability to understand and the willingness to sign a written informed consent

Exclusion Criteria:

- Women who are pregnant or lactating.

- Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for
nitrosoureas or mitomycin C) prior to entering the study or those who have not
recovered from adverse events due to agents administered more than 4 weeks earlier.

- Patients with previous high dose chemotherapy with autologous stem cell rescue bone
marrow transplantation.

- Use of any investigational agents within 4 weeks of study enrollment.

- History of severe allergic reactions to paclitaxel or docetaxel including severe
hypersensitivity reactions defined as greater than or equal to 3 based on NCI CTC
version 2.

- Uncontrolled intercurrent illness including, but not limited to ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia or psychiatric illness/social situations that would limit compliance with
study requirements, as determined by the investigator.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


United States: Food and Drug Administration

Study ID:




Start Date:

Completion Date:

Related Keywords:

  • Neoplasms
  • Neoplasms



Dana Farber Cancer Institute Boston, Massachusetts  02115
Beth Israel-Deaconess Medical Center Boston, Massachusetts  02215